A digital health revolution is underway, and healthcare is evolving like never before. Cross-industry collaboration provides the opportunity to create better healthcare solutions and seamless experiences for patients and care givers, at scale.
Novartis Pharmaceuticals UK recently launched the Novartis Biome UK Heart Health Catalyst 2022, in partnership with Medtronic ltd, RYSE Asset Management, Chelsea and Westminster Hospital NHS Foundation Trust, and its official charity CW+, to support this transition.
The world-first investor partnership presents an unrivalled opportunity to boldly remodel patient care pathways for people living with cardiovascular disease (CVD), a leading cause of death in the UK¹.
The programme partners are combining their expertise and experience to identify and scale innovation in the at-home blood pressure management and non-invasive lipid testing space.
Successful applicants will receive:
- Unrivalled support from industry-leading partners during the competition process.
- Opportunity of investment up to £3 million provided by RYSE Asset Management, subject to due diligence at RYSE’s discretion.
- Access to the Novartis Biome UK eco-system.
- Opportunities to work with our NHS partners to set up and deliver a pilot evaluation of the winning innovation.
Applications are open until 31 August to health-tech start-up founders, researchers, and technologists working on digital and data-driven solutions that could enable system-wide change in CVD.
Shortlisted organisations and individuals will be invited to pitch in front of an expert audience from across the healthcare system at the Novartis Biome UK Heart Health Catalyst 2022 Pitchfest event at the Healthcare Excellence Through Technology (HETT) conference on 27 September 2022 at 2pm, where the winners will subsequently be announced.
 British Heart Foundation. UK Factsheet. January 2020. BHF UK CVD Factsheet